What Sanzyme does

Sanzyme Private Limited is an Indian biopharmaceutical manufacturer founded in 1969 and headquartered in Hyderabad, specializing in the development and production of human-derived gonadotropins (HMG, FSH, HCG), sex hormones (Progesterone, Hydroxyprogesterone Caproate, Testosterone Undecanoate), and specialty probiotics. The company operates an integrated manufacturing model at its Genome Valley facility in Hyderabad, covering both drug substance (API) and finished formulation production, with multi-step chromatography purification, dedicated bio-analytical, chemical, microbiology, and immunoassay laboratories, and production capacity of 10 million gonadotropin vials per annum scalable to 20 million. The facility holds EU GMP and PIC/s certifications for drug product manufacturing and the R&D center is approved by India's DSIR. Quality has been substantiated through bioanalytical characterization, preclinical GLP studies, and Phase 3 clinical trials demonstrating non-inferiority to innovator gonadotropin products in IVF outcomes.

Sanzyme monetizes through two parallel go-to-market channels. The first is contract manufacturing services, supplying gonadotropin APIs and finished formulations to pharmaceutical marketing companies under partner brand names — currently the largest manufacturer serving the Indian gonadotropin market with named customers including Ferring India, Sun Pharma, Serum Institute of India, and JB Pharma, plus a long-standing export relationship with Sankyo/Daiichi-Sankyo for the Japanese market. The second is direct-to-patient and fertility-center distribution through a network of channel partners covering Asia, Africa, MENA, LATAM, and CIS regions, with stated intent to extend into EU and USA markets. The company's specialty probiotic portfolio includes the Sporlac franchise (India's largest prescribed probiotic brand for over five decades) plus branded products targeting chronic kidney disease, renal stones, NAFLD/NASH, and gastrointestinal disorders.

Name

Sanzyme

Legal name

SANZYME PRIVATE LIMITED

Website

https://sanzyme.com

Company type

Private

Founded year

1969

Operating status

Operating

Headcount range

501–1,000 employees

Short description

Sanzyme Private Limited is a Hyderabad-based biopharmaceutical manufacturer founded in 1969 that produces human-derived gonadotropins, sex hormones, and specialty probiotics, supplying global pharma companies via contract manufacturing and serving patients through channel partners across 30 countries.

Ownership category

akta.pro rank

Product category

Fertility Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Women’s Health & Reproductive Specialty Pharmaceuticals (HLAIACAN)

akta.pro secondary industry

Generic Finished Dosage Form (FDF) Manufacturing (HLAIABAH)

Keywords

• Gonadotropin manufacturing
• Fertility pharmaceuticals
• Specialty probiotics
• Contract pharmaceutical manufacturing
• Sex hormone production

Headquarters

HQ city

Hyderabad

HQ country

India

HQ region

Asia

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Supply Chain, Infrastructure, Marketing or Sales

Revenue model

1. Contract Manufacturing Services: Manufacturing gonadotropins, sex hormones, and specialty probiotics for pharmaceutical marketing companies under partner brand names. Currently serving Indian market clientele including Ferring India, Sun Pharma, Serum Institute of India, and JB Pharma. Export to Japan since 1969 via joint venture with Sankyo (now Daiichi-Sankyo).
2. Proprietary Brand Sales: Direct-to-patient and fertility center sales through channel partners across global markets. Products include Sanzyme brands available through distributors in Asia, Africa, MENA, LATAM, and CIS regions.

Pricing tiers

Go-to-market motion1 record

Distribution channels3 records

Marketing channels4 records

Core offering

Sanzyme manufactures human-derived gonadotropins (HMG, FSH, HCG), sex hormones (Progesterone, Hydroxyprogesterone Caproate, Testosterone Undecanoate), and specialty probiotics used in fertility treatments, pregnancy support, hormone replacement therapy, and renal/gastrointestinal conditions. The company operates as a contract manufacturing organization (CMO) supplying both Active Pharmaceutical Ingredients/Drug Substance (API/DS) and Finished Formulations/Drug Product (FF/DP) to pharmaceutical marketing companies globally under partner brand names, while also distributing its own branded products through channel partners in Asia, Africa, MENA, LATAM, and CIS regions.

Product overview

Sanzyme is a pharmaceutical/biotechnology company specializing in the development and manufacturing of three product categories: Gonadotropins, Sex Hormones, and Specialty Probiotics. The Gonadotropin portfolio includes HMG (Human Menopausal Gonadotropin), FSH (Follicle Stimulating Hormone), and HCG (Human Chorionic Gonadotropin) - all used in Assisted Reproductive Technology (ART) treatments for infertility. The Sex Hormones portfolio includes Progesterone, Hydroxyprogesterone Caproate, and Testosterone Undecanoate for pregnancy support and hormone replacement therapy. The Specialty Probiotics portfolio includes 9 branded products (LOBUN® FORTE, LOBUN®, OXALO FORTE, OXALOTM, NUBACT XL, SPORLAC DS, SPORLAC® PLUS, BACICLASI, SOLIB) addressing conditions including Chronic Kidney Disease, kidney stones, liver disease, inflammatory bowel disease, and diarrheal disorders. Sanzyme operates as a contract manufacturing organization (CMO) supplying both API/Drug Substance and Finished Formulations globally, with EU GMP certified facilities in Hyderabad, India.

Differentiator

Problem solved

Functional benefit

Brands

• GYNOGENTM: Trademark brand for HMG (Human Menopausal Gonadotropin) products for export purposes
• ENDOGENTM
• PUBERGENTM
• SUGESTTM
• GYNONYS
• TESTOKITM
• Sporlac
• LOBUN
• OXALO

Products and services

• HMG (Human Menopausal Gonadotropin) - GYNOGEN Human Menopausal Gonadotropin containing FSH and LH in a 1:1 ratio, extracted from urine of postmenopausal women. Used for controlled ovarian stimulation in ART (IUI, IVF, ICSI) and spermatogenesis in men with hypogonadotrophic hypogonadism. Available in lyophilized (75 IU, 150 IU) and liquid multi-dose vials (600 IU, 1200 IU). Marketed as GYNOGEN for export markets.
• FSH (Follicle Stimulating Hormone) - ENDOGEN Follicle Stimulating Hormone used for controlled ovarian stimulation to recruit and develop multiple eggs during ovulation induction cycles in women undergoing Assisted Reproductive Technology (ART) such as IUI, IVF, and ICSI. Can be used alone or with hMG. Marketed as ENDOGEN for export markets.
• HCG (Human Chorionic Gonadotropin) - PUBERGEN Human Chorionic Gonadotropin extracted from urine of pregnant women. Used as ovulation trigger for final egg maturation and release in ART procedures. Also stimulates corpus luteum to secrete progesterone for luteal phase support. Available in strengths: 500 IU, 1000 IU, 1500 IU, 2000 IU, 5000 IU, 7500 IU, 10000 IU. Marketed as PUBERGEN for export markets.
• Progesterone - SUGEST

Quantifiable outcome

• Phase 3 clinical studies showed Sanzyme gonadotropins are Non-Inferior compared to Innovator products in terms of Number of Oocytes retrieved in women undergoing IVF
• +2 more outcomes

Named customers4 records

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• Sankyo (now Daiichi-Sankyo)foundationalStrategic or Co-development Partner · 1 January 1969In 1969, Sanzyme entered into a Joint Venture with Sankyo (now Daiichi-Sankyo) to manufacture gonadotropins for export to Japan. This partnership established Sanzyme's foundation in biological hormones manufacturing and provided the technological foundation for their subsequent path-breaking work in the gonadotropin space.

Scale indicators7 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• Ferring Pharmaceuticals: Global leader in reproductive health and women's health, manufacturing gonadotropins (e.g., Bravelle/Menopur) and ART therapies. Directly comparable as a fertility-pharma specialist, and notably one of Sanzyme's largest Indian customers (Ferring India).
• Merck KGaA (Life Science / Healthcare): Markets Gonal-f (r-FSH), Ovidrel (r-HCG), and Cetrotide — the leading recombinant gonadotropin franchise used in IVF globally. Most relevant direct competitor given overlap in fertility therapeutics and global ART footprint.
• Organon & Co. Spun out of Merck to focus on women's health, including the Follistim (r-FSH), Ganirelix, and Crinone franchises. A direct peer in fertility/ART pharmaceuticals with comparable global commercialization model.
• IBSA Institut Biochimique SA: Swiss-based specialty pharma known for highly-purified urinary HMG (Meriofert) and other gonadotropin preparations. Highly comparable as a urinary-derived gonadotropin manufacturer competing with Sanzyme in similar IVF markets.
• Gedeon Richter Plc. Hungarian pharma with a dedicated women's health/fertility franchise (Bemfola biosimilar r-FSH, gonadotropins). Comparable as a fertility-pharma specialist operating across EU/CIS geographies similar to Sanzyme's footprint.
• Bharat Serums and Vaccines Limited (BSV): Indian biopharmaceutical company specializing in fertility, women's health, and biological products including HMG, HCG, and recombinant gonadotropins. Directly comparable Indian-headquartered peer competing in the same domestic market.
• Intas Pharmaceuticals: Large Indian pharmaceutical company with a women's health and fertility portfolio including gonadotropins. Comparable as a domestic competitor and similar CMO-oriented Indian pharma.
• Theramex Healthcare:

Market position

Strengths5 records

Weaknesses2 records

Competitive moat5 records

Key risks5 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/watch?v=Ugs2QiQ0c4I
• LinkedInlinkedin.com/company/sanzyme
• Xx.com/sanzyme
• Facebookfacebook.com/sanzyme

Compliance5 records

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Sanzyme